GSK hands off Lyell cell therapy to Adaptimmune

Today's Big News

Oct 25, 2022

Biogen insists Eisai relationship is 'solid' as questions remain over lecanemab commercialization details

Novartis stops liver transplant program after Astellas drug beats its CD40 prospect in phase 2

GSK axes Lyell cell therapy, passes programs to Adaptimmune

Astellas continues gene therapy push with $50M for stake in Taysha, options on 2 CNS assets

Diffusion may disperse: Biotech’s board calls for strategic review of all options, including sale

Inotrem looks to regulatory agencies after COVID treatment hits phase 2 goals

GSK's ViiV gives early look at HIV broadly neutralizing antibody's power, eyes long-acting combo trial

Overeating sweet treats? Scientists discover what drives this desire

 

Featured

Biogen insists Eisai relationship 'solid' as questions remain over lecanemab commercialization

Biogen may still be basking in the positive phase 3 data of its Eisai-partnered Alzheimer’s drug lecanemab, but the big pharma's CEO has remained vague on exactly what role his company will play in the therapy's commercialization.
 

Top Stories

Novartis stops liver transplant program after Astellas drug beats its CD40 prospect in phase 2

The CD40 space has claimed another victim. One year after disclosing a kidney transplant flop, Novartis has stopped work on iscalimab in liver transplantation after a phase 2 trial delivered lackluster results.

GSK axes Lyell cell therapy, passes programs to Adaptimmune

GSK has axed its NY-ESO-1 T-cell receptor pact with Lyell Immunopharma, with the Big Pharma transferring the program to Adaptimmune. It means that months after stopping enrollment in a study of its first-generation NY-ESO-1 candidate, GSK has walked away from a $1 billion-plus pact with Lyell that could have delivered enhanced successors. 

Astellas continues gene therapy push with $50M for stake in Taysha, options on 2 CNS assets

Astellas will sink $50 million into Taysha Gene Therapies in exchange for a 15% stake in the biotech and the option to license its clinical-stage candidates for two rare neurological disorders.

Diffusion may disperse: Biotech’s board calls for strategic review of all options, including sale

Diffusion Pharmaceuticals is evaluating its options amid the prolonged bear market, including partnerships, licensing deals, divestiture for some of its tech or selling off the whole biotech.

Inotrem looks to regulatory agencies after COVID treatment hits phase 2 goals

Though many COVID-19 treatments are in development, few have yet to cross the approval threshold in the U.S. or Europe. French biotech Inotrem hopes to change that, posting phase 2 data that show its only clinical-stage compound could help critically ill COVID patients.

GSK's ViiV gives early look at HIV broadly neutralizing antibody's power, eyes long-acting combo trial

Broadly neutralizing antibodies hold promise as potential longer-term HIV options, and GSK’s ViiV Healthcare has provided encouraging early proof-of-concept data for such a candidate it licensed from the NIH.

Overeating sweet treats? Scientists discover what drives this desire

Neurons in the part of the brain that controls the fear response may also be responsible for the tendency to overeat fatty, sugary foods.

Zolgensma's slowdown unrelated to gene therapy deaths, Novartis CEO says

Novartis’ gene therapy Zolgensma ranks among six drugs that the Swiss pharma counts as its major growth drivers with multibillion-dollar peak sales potential. But the drug was missing from a list of the company's top performers in the third quarter.

23andMe betting big on its genomic health service that integrates genetics with primary care

23andMe is focused on using Lemonaid Health's virtual care and online pharmacy capabilities to build out genetically-driven telehealth and pharmacogenomic services.

Despite Aduhelm cost cuts, Biogen still has Alzheimer's manufacturing firepower on deck, CFO says

Should its Eisai-partnered Alzheimer's disease prospect lecanemab win an approval at the FDA this coming January, Biogen already has facilities on deck to crank out the amyloid plaque-busting antibody, plus “a little over $100 million of inventory on hand as of the end of the quarter,” the company's CFO said Tuesday.

Verily to build data-powered registry of IBD patients to accelerate Crohn's, colitis research

Verily is on the up-and-up—as in, re-upping a team-up with the Crohn’s and Colitis Foundation to help spur research into inflammatory bowel disease forward.

2 Methodist Health System employees killed in maternity ward shooting

The suspect was on parole for aggravated robbery and was permitted to visit the hospital with an ankle bracelet as his girlfriend gave birth, according to the Dallas Police Department.
 
Fierce podcasts

Don't miss an episode

'The Top Line': Pfizer takes kickback lawsuit to the Supreme Court, plus a special report on the top 10 vaccine companies

This week on "The Top Line," we talk about our special report on the top 10 vaccine company rankings. We also report the news on Pfizer's kickback lawsuit, OTC hearing aids and more.
 

Resources

eBook

Optimize Digital Engagement Across the Patient Journey

Improve patient engagement, adherence, and outcomes
Whitepaper

EHR vs Registry Data for RWE – Heart Failure as a Case Study

Electronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs?
eBook

How the Cloud Puts Precision Medicine Within Reach for Startups

In this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities.
eBook

The Essential Components of a Successful Remote Patient Monitoring Program

Looking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs.
eBook

Optimize the value and impact of your real-world data

With real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy.
Whitepaper

Navigating the Data Deluge: Turning Data Into Insight Across the Health Care and Life Sciences Industries

Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem.

Whitepaper

A Guide to Pre-Validated Software-as-a-Service LIMS

SaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security.
Whitepaper

Cutting Through the Noise: Crossing the New Real World Data Landscape

Read about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward.
Whitepaper

Commercializing Gene Therapies, Part I - Introduction

This paper is the first in a 4-part series focused on developing commercial models for gene therapies
Video

Building a Broader Tissue Research Ecosystem

Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue.
Video

Improve Life Sciences Research with AI Workflow Automation

Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster?
Whitepaper

The Most Suitable Dosage Form Technologies for the Oral Delivery of Lipid-Based Formulations

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?
Research

Versatility of Softgel Technology - Encapsulation of a Volatile Compound

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.
Whitepaper

Lipid-Based Drug Delivery System to Bring Poorly Soluble Drugs to Market

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?
Whitepaper

Formulation Strategies When Transitioning From Vial to PFS

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

Webinar

The Faster Path From Pre-Filled Syringe to Auto-Injector

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.
Custom Resource Center

Scaling life sciences companies: Discover resources to support growth and innovation

Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals.

Whitepaper

Softgel Formulation Enables Oral Delivery of Testosterone

Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy.

Whitepaper

Strategies for the Optimal Scale-up & Tech Transfer of Oral Small Molecules

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

eBook

Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities

Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities

Whitepaper

Catalent Pulmonary & Nasal Delivery Capabilities Sheet

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?

Whitepaper

Intranasal Drug Product Development: Formulation to Manufacturing

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?